Most human clinical trials have focused on the use of HDAC inhibitors in GBM and a recent systematic review was published supporting the use of valproic acid to increase overall survival in GBM, although prospective randomized control trials are needed to confirm these findings (209). Here, HDAC9 is linked to glioblastoma.